Shares of Spain's Zeltia shot up on the news that it has positive late-stage data for the ovarian cancer drug Yondelis to support its application for marketing approval. The developer plans to file in the U.S. and Europe in the last quarter of the year. Researchers for the company say that the data demonstrates that a combination of Yondelis and Doxil was significantly better than Doxil alone in halting tumor growth.
- read the report from The Guardian